다우존스 지수

실시간 차트, 분석 도구 및 가격을 받으려면 등록하세요.

등록

홈
인베스팅
주식
미국
NASDAQ
Galmed Pharmaceuticals Ltd (GLMD)
Galmed Pharmaceuticals Ltd (GLMD) 뉴스

GLMD

Galmed Pharmaceuticals (GLMD)

Galmed Pharmaceuticals Ltd

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:GLMD

1 2 3 4 5 6 7 8 9 10 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/04/05	06:06	PR Newswire (US)	Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023	NASDAQ:GLMD	Galmed Pharmaceuticals Ltd
2024/03/15	22:00	PR Newswire (US)	Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis	NASDAQ:GLMD	Galmed Pharmaceuticals Ltd
2024/02/15	04:14	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:GLMD	Galmed Pharmaceuticals Ltd
2024/02/13	06:15	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:GLMD	Galmed Pharmaceuticals Ltd
2023/11/30	14:15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:GLMD	Galmed Pharmaceuticals Ltd
2023/11/23	06:48	Edgar (US Regulatory)	Form POS AM - Post-Effective amendments for registration statement	NASDAQ:GLMD	Galmed Pharmaceuticals Ltd
2023/11/21	06:37	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GLMD	Galmed Pharmaceuticals Ltd
2023/11/21	06:32	PR Newswire (US)	Galmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a Study	NASDAQ:GLMD	Galmed Pharmaceuticals Ltd
2023/11/02	05:15	Edgar (US Regulatory)	Form POS AM - Post-Effective amendments for registration statement	NASDAQ:GLMD	Galmed Pharmaceuticals Ltd
2023/09/26	21:51	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GLMD	Galmed Pharmaceuticals Ltd
2023/09/26	21:30	PR Newswire (US)	Galmed Announces Allowance of New Patent for Aramchol for the Treatment of Pulmonary and Dermal Fibrosis	NASDAQ:GLMD	Galmed Pharmaceuticals Ltd
2023/09/23	05:15	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GLMD	Galmed Pharmaceuticals Ltd
2023/09/23	05:05	PR Newswire (US)	Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification	NASDAQ:GLMD	Galmed Pharmaceuticals Ltd
2023/09/21	20:30	Edgar (US Regulatory)	Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]	NASDAQ:GLMD	Galmed Pharmaceuticals Ltd
2023/09/21	05:30	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GLMD	Galmed Pharmaceuticals Ltd
2023/09/14	05:01	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GLMD	Galmed Pharmaceuticals Ltd
2023/08/10	05:43	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GLMD	Galmed Pharmaceuticals Ltd
2023/08/10	05:30	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GLMD	Galmed Pharmaceuticals Ltd
2023/08/03	05:30	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GLMD	Galmed Pharmaceuticals Ltd
2023/07/21	23:12	Edgar (US Regulatory)	Form SC 13G - Statement of acquisition of beneficial ownership by individuals	NASDAQ:GLMD	Galmed Pharmaceuticals Ltd
2023/07/18	22:25	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GLMD	Galmed Pharmaceuticals Ltd
2023/07/18	22:23	Edgar (US Regulatory)	Form 424B4 - Prospectus [Rule 424(b)(4)]	NASDAQ:GLMD	Galmed Pharmaceuticals Ltd
2023/07/14	22:44	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GLMD	Galmed Pharmaceuticals Ltd
2023/07/14	22:30	PR Newswire (US)	Galmed Pharmaceuticals Announces Pricing of $7 Million Public Offering	NASDAQ:GLMD	Galmed Pharmaceuticals Ltd
2023/07/14	06:08	Edgar (US Regulatory)	Form F-1/A - Registration statement for certain foreign private issuers: [Amend]	NASDAQ:GLMD	Galmed Pharmaceuticals Ltd
2023/07/13	06:29	Edgar (US Regulatory)	Form F-1/A - Registration statement for certain foreign private issuers: [Amend]	NASDAQ:GLMD	Galmed Pharmaceuticals Ltd
2023/07/10	21:10	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GLMD	Galmed Pharmaceuticals Ltd
2023/07/10	21:10	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GLMD	Galmed Pharmaceuticals Ltd
2023/07/10	21:00	PR Newswire (US)	Galmed to employ OnKai's disruptive Artificial Intelligence (AI) in its Planned Phase 2a Clinical Trial in PSC	NASDAQ:GLMD	Galmed Pharmaceuticals Ltd
2023/06/28	21:41	Edgar (US Regulatory)	Free Writing Prospectus - Filing Under Securities Act Rules 163/433 (fwp)	NASDAQ:GLMD	Galmed Pharmaceuticals Ltd

검색 관련기사 보기:NASDAQ:GLMD

1 2 3 4 5 6 7 8 9 10 다음 >>

Verizon Communications

Health Care Select Sector

BNP Paribas (QX)

JP Morgan Chase

Invesco QQQ Trust Series 1

American Express

Energy Select Sector SPDR

Financial Select Sector

Delayed Upgrade Clock

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관